​

MoonLake Immunotherapeutics Ownership | Who Owns MoonLake Immunotherapeutics?

OverviewForecastRevenueFinancialsChart

MoonLake Immunotherapeutics Ownership Summary

MoonLake Immunotherapeutics is owned by 94.45% institutional investors, 15.34% insiders. Bvf inc/il is the largest institutional shareholder, holding 31.40% of MLTX shares. T. Rowe Price Health Sciences is the top mutual fund, with 1.73% of its assets in MoonLake Immunotherapeutics shares.

MLTX Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockMoonLake Immunotherapeutics94.45%15.34%-9.78%
SectorHealthcare Stocks 279.15%10.63%-189.78%
IndustryBiotech Stocks 63.94%10.67%25.38%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Bvf inc/il19.75M31.40%$1.07B
Cormorant asset management, lp8.49M13.50%$459.96M
Fmr6.34M10.08%$343.39M
Price t rowe associates inc /md/3.34M5.32%$181.06M
Avoro capital advisors2.77M4.40%$150.00M
Paradigm biocapital advisors lp1.77M2.82%$95.97M
Goldman sachs group1.67M2.66%$90.68M
Holocene advisors, lp1.59M2.52%$85.84M
Westfield capital management co lp1.31M2.09%$71.02M
Federated hermes1.28M2.04%$69.31M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Bvf inc/il19.75M36.25%$1.07B
Cormorant asset management, lp8.49M25.26%$459.96M
Saturn v capital management346.11K7.34%$18.74M
Ghost tree capital300.00K4.13%$13.19M
5am venture management282.31K3.65%$15.29M
Paradigm biocapital advisors lp1.77M3.34%$95.97M
Bioimpact capital315.23K2.42%$17.07M
Avoro capital advisors2.77M2.12%$150.00M
Finepoint capital lp447.94K1.48%$24.26M
Integral health asset management200.00K0.92%$10.83M

Top Buyers

HolderShares% AssetsChange
Fmr6.34M0.02%1.39M
Paradigm biocapital advisors lp1.77M3.34%840.73K
Polar capital1.10M0.33%600.00K
Price t rowe associates inc /md/3.34M0.02%363.39K
Walleye capital208.90K0.03%208.90K

Top Sellers

HolderShares% AssetsChange
Bvf inc/il19.75M36.25%-2.00M
T. rowe price investment management---1.10M
Logos global management lp---750.00K
Perceptive advisors---339.01K
Ecor1 capital---332.52K

New Positions

HolderShares% AssetsChangeValue
Dimensional fund advisors lp64.38K0.00%64.38K$3.49M
Peak6 investments13.00K0.00%13.00K$571.61K
Bnp paribas arbitrage, snc7.63K0.00%7.63K$413.33K
Jefferies financial group6.25K0.00%6.25K$338.44K
Birchview capital, lp4.00K0.18%4.00K$216.60K

Sold Out

HolderChange
National bank of canada /fi/-2.00
Td private client wealth-9.00
Geneos wealth management-14.00
Skopos labs-78.00
Nationale-nederlanden powszechne towarzystwo emerytalne-85.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Mar 31, 202515019.05%59,722,976-5.57%940.93%72-4343.33%
Dec 31, 20241246.90%63,224,5991.80%1001.03%70-3020.00%
Sep 30, 2024116-1.69%62,108,6632.42%981.05%7120.34%25-35.90%
Jun 30, 2024118-9.92%60,643,9062.22%961.08%59-6.35%39-7.14%
Mar 31, 2024131-11.49%59,326,406-0.00%940.97%63-30.77%4220.00%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
T. Rowe Price Health Sciences1.10M1.73%-41.29K
Polar Capital Biotech S Inc1.00M1.58%-
Fidelity Select Health Care753.79K1.19%1.00K
Westfield Capital Mgt Co Sm-Cap Gr Eq704.82K1.11%56.75K
Fidelity Growth Compy Commingled Pl S688.17K1.08%554.00
Federated Hermes Kaufmann Growth665.00K1.05%-
Federated Hermes Kaufmann R665.00K1.05%-
T. Rowe Price Integrated US SmCapGrEq598.31K0.95%299.16K
US Small-Cap Growth II Equity Comp523.89K0.83%-134.19K
T. Rowe Price New Horizons523.89K0.83%-37.38K

Recent Insider Transactions

DateNameRoleActivityValue
Jul 03, 2025Moukheibir Catherine-Sell$1.15M
Oct 04, 2024BVF PARTNERS L P/IL Sell$6.63M
Oct 04, 2024BVF PARTNERS L P/IL Sell$41.84M
Oct 04, 2024BVF PARTNERS L P/IL Sell$51.53M
Oct 04, 2024Sturge Simon-Sell$9.19M

Insider Transactions Trends

DateBuySell
2024 Q2--
2024 Q1-21
2023 Q442
2023 Q228-
2022 Q21-

MLTX Ownership FAQ

Who Owns MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics shareholders are primarily institutional investors at 94.45%, followed by 15.34% insiders and -9.79% retail investors. The average institutional ownership in MoonLake Immunotherapeutics's industry, Biotech Stocks , is 63.94%, which MoonLake Immunotherapeutics exceeds.

Who owns the most shares of MoonLake Immunotherapeutics?

MoonLake Immunotherapeutics’s largest shareholders are Bvf inc/il (19.75M shares, 31.40%), Cormorant asset management, lp (8.49M shares, 13.50%), and Fmr (6.34M shares, 10.08%). Together, they hold 54.99% of MoonLake Immunotherapeutics’s total shares outstanding.

Does Blackrock own MoonLake Immunotherapeutics?

BlackRock is not among the top 10 institutional shareholders of MoonLake Immunotherapeutics.

Who is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested?

Bvf inc/il is MoonLake Immunotherapeutics’s biggest shareholder by percentage of total assets invested, with 36.25% of its assets in 19.75M MoonLake Immunotherapeutics shares, valued at 1.07B$.

Who is the top mutual fund holder of MoonLake Immunotherapeutics shares?

T. Rowe Price Health Sciences is the top mutual fund holder of MoonLake Immunotherapeutics shares, with 1.73% of its total shares outstanding invested in 1.1M MoonLake Immunotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools